title: Low-dose aspirin before spinal surgery: results of a survey among neurosurgeons in Germany.
abstract: The main problem faced by the increasing numbers of patients presenting for spinal surgery are receiving concurrent medication with low-dose aspirin, leading to dysfunctional circulating platelets. The contribution of low-dose aspirin to increased peri-operative risk of bleeding and blood loss is a contentious issue with conflicting published results from different surgical groups. Data from neurosurgical spine patients is sparse, but aspirin has been identified as an important risk factor in the development of post-operative hematoma following intracranial surgery. We surveyed the opinions and working practices of the neurosurgical facilities performing spinal operations in Germany regarding patients who present for elective spinal surgery. Identical questionnaires were sent to 210 neurosurgical facilities and proffered five main questions: (1) the adherence of any policy of stopping aspirin pre-operatively, (2) the personal risk assessment for patients with spinal surgery under low-dose aspirin medication, (3) the preferred method of treatment for excessive bleeding in this context, (4) personal knowledge of hemorrhagic complications in this group of patients, and (5) the characteristics of the neurosurgical units concerned. There were 145 (69.1%) responses of which 142 (67.6%) were valid. Of the respondents, 114 (80.3%) had a (written) departmental policy for the discontinuation of pre-operative aspirin treatment, 28 (19.7%) were unaware of such a policy. The mean time suggested for discontinuation of aspirin pre-operatively was 6.9 days (range: 0-21 days), with seven respondents who perform the operations despite the ongoing aspirin medication. Ninety-four respondents (66.2%) considered that patients taking low-dose aspirin were at increased risk for excessive peri-operative hemorrhage or were indetermined (8.6%), and 73 (51.4%) reported having personal experience of such problems. Ninety-two respondents (65.5%) would use special medical therapy, preferably Desmopressin alone or in combination with other blood products or prohemostatic agents (46.1%), if hemorrhagic complications developed intra- or post-operatively. The average number of spinal operations per year in each service was 607.9 (range: 40-1,500). Despite the existence of distinct departmental policies concerning the discontinuation of low-dose aspirin pre-operatively in the majority of neurosurgical facilities performing spinal operations, there is a wide range of the moment of this interruption with an average of 7 days. Two-thirds of the respondents felt that aspirin was a risk factor for hemorrhagic complications associated with spinal procedures, and more than half of the interviewees reported having personal experience of such problems. Finally, various medicamentous methods of counteracting aspirin-induced platelet dysfunction and excessive bleeding in this context are elicited, discussed and evaluated.
authors.affiliation: Department of Neurosurgery, University Hospital RWTH Aachen, Pauwelsstr, 30, 52057 Aachen, Germany. Marcus.Korinth@post.rwth-aachen.de
authors.forename: Marcus C
authors.initials: MC
authors.lastname: Korinth
authors.forename: Joachim M
authors.initials: JM
authors.lastname: Gilsbach
authors.forename: Martin R
authors.initials: MR
authors.lastname: Weinzierl
mesh_terms: D001241:Aspirin / Q000009:adverse effects*; D016063:Blood Loss, Surgical / Q000517:prevention & control; D003625:Data Collection / Q000706:statistics & numerical data*; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005858:Germany; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D019635:Neurosurgical Procedures / Q000009:adverse effects* / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011300:Preoperative Care / Q000009:adverse effects*; D018570:Risk Assessment; D013131:Spine / Q000601:surgery*
chemical_list: D006490:Hemostatics; D010975:Platelet Aggregation Inhibitors; D003894:Deamino Arginine Vasopressin; D001241:Aspirin